Worldwide Clinical Trials employs more than 1,400 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. One of the world’s leading, full-service contract research organizations (CROs), we partner with sponsors in the pharmaceutical and biotechnology industries to deliver fully integrated clinical development and bioanalytical services, extending from first-inhuman through phase IV studies. Grounded in medicine and science, Worldwide Clinical Trials enables sponsors to move from medical discovery into clinical development and commercialization, helping bring innovative solutions to market that deliver enhanced value and improve patient lives. Our employees are among the best in their fields – clinicians, scientists, operational and regulatory specialists who offer expertise across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune mediated inflammatory disorders (IMID), and rare diseases.
UNDERSTANDING THE UNIQUE CHALLENGES IN RESPIRATORY CLINICAL RESEARCH
At Worldwide Clinical Trials, our experts understand that the commercial viability of therapeutics for chronic respiratory disorders is influenced by a range of factors, including perceived value and therapeutic novelty. This has particular relevance to illnesses with established pharmacotherapy such as asthma and COPD. Worldwide Clinical Trails’ philosophy of employing expert clinical trial methodology, combined with our commitment to innovation, helps us deliver data relevant to multiple stakeholder perspectives and appropriate to each phase of your drug or device development. Our close relationships with opinion leaders and practitioners in respiratory medicine ensure that complex study objectives and eligibility criteria evolve into a plan that delivers reliable metrics, consistently met timelines, and impeccable data. Our team has success in overcoming the unique challenges in conducting trials in respiratory disorders, including for example, determining the allergic status of patients with asthma and managing co-morbidity often associated with COPD.